Bernard Coulie - May 14, 2021 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role
President and CEO, Director
Signature
/s/ Mike Ouimette, attorney-in-fact
Stock symbol
PLRX
Transactions as of
May 14, 2021
Transactions value $
-$100,224
Form type
4
Date filed
5/17/2021, 07:34 PM
Next filing
Jun 15, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLRX Common Stock Sale -$85.5K -3K -0.66% $28.53 454K May 14, 2021 See footnote F1, F2, F3
transaction PLRX Common Stock Sale -$14.7K -503 -0.11% $29.28 453K May 14, 2021 See footnote F1, F3, F4
holding PLRX Common Stock 54.8K May 14, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.0500 to $29.0100, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.2000 to $29.3500, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.